CD45 alleviates airway inflammation and lung fibrosis by limiting expansion and activation of ILC2s
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2215941120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Guangwei Cui und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immune Regulation, Department of Virus Research, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Group 2 innate lymphoid cells (ILC2s) are critical for the immune response against parasite infection and tissue homeostasis and involved in the pathogenesis of allergy and inflammatory diseases. Although multiple molecules positively regulating ILC2 development and activation have been extensively investigated, the factors limiting their population size and response remain poorly studied. Here, we found that CD45, a membrane-bound tyrosine phosphatase essential for T cell development, negatively regulated ILC2s in a cell-intrinsic manner. ILC2s in CD45-deficient mice exhibited enhanced proliferation and maturation in the bone marrow and hyperactivated phenotypes in the lung with high glycolytic capacity. Furthermore, CD45 signaling suppressed the type 2 inflammatory response by lung ILC2s and alleviated airway inflammation and pulmonary fibrosis. Finally, the interaction with galectin-9 influenced CD45 signaling in ILC2s. These results demonstrate that CD45 is a cell-intrinsic negative regulator of ILC2s and prevents lung inflammation and fibrosis via ILC2s.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Immune Regulation, Department of Virus Research, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
- Laboratory for Prediction of Cell Systems Dynamics, RIKEN Center for Biosystems Dynamics Research, Osaka 565-0874, Japan.
- Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
- Department of Medical Biology, Graduate School of Medicine, Akita University, Akita 010-8543, Japan.
ORCID-Profile: Nozomi Hojo, Ryo Yamada, Takashi Ebihara, Katsuyuki Shiroguchi
Förderung
- MEXT | Japan Society for the Promotion of Science
Zitieren
APA
Cui, G., Shimba, A., Jin, J., Hojo, N., Asahi, T., Abe, S., Ejima, A., Okada, S., Ohira, K., Kato, R., Tani-Ichi, S., Yamada, R., Ebihara, T., Shiroguchi, K., & Ikuta, K. (2023). CD45 alleviates airway inflammation and lung fibrosis by limiting expansion and activation of ILC2s. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2215941120
Vancouver
Cui G, Shimba A, Jin J, Hojo N, Asahi T, Abe S, et al. CD45 alleviates airway inflammation and lung fibrosis by limiting expansion and activation of ILC2s. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2215941120
BibTeX
@article{Cui2023,
author = {Cui, Guangwei and Shimba, Akihiro and Jin, Jianshi and Hojo, Nozomi and Asahi, Takuma and Abe, Shinya and Ejima, Aki and Okada, Shinri and Ohira, Keizo and Kato, Ryoma and Tani-Ichi, Shizue and Yamada, Ryo and Ebihara, Takashi and Shiroguchi, Katsuyuki and Ikuta, Koichi},
title = {CD45 alleviates airway inflammation and lung fibrosis by limiting expansion and activation of ILC2s},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2215941120}
}
EUVIMED